High-Dose Interferon Alfa-2b Significantly Prolongs Relapse-Free and Overall Survival Compared With the GM2-KLH/QS-21 Vaccine in Patients With Resected Stage IIB-III Melanoma: Results of Intergroup Trial E1694/S9512/C509801
The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
PURPOSE: Vaccine alternatives to high-dose interferon alfa-2b therapy (HDI), the current standard adjuvant therapy for high-risk melanoma, are of interest because of toxicity associated with HDI. The GM2 ganglioside is a well-defined melanoma antigen, and anti-GM2 antibodies have been associated with improved prognosis. We conducted a prospective, randomized, intergroup trial to evaluate the efficacy of HDI for 1 year versus vaccination with GM2 conjugated to keyhole limpet hemocyanin and administered with QS-21 (GMK) for 96 weeks (weekly × 4 then every 12 weeks × 8). PATIENTS AND METHODS: Eligible patients had resected stage IIB/III melanoma. Patients were stratified by sex and number of positive nodes. Primary end points were relapse-free survival (RFS) and overall survival (OS). RESULTS: Eight hundred eighty patients were randomized (440 per treatment group); 774 patients were eligible for efficacy analysis. The trial was closed after interim analysis indicated inferiority of GMK compared with HDI. For eligible patients, HDI provided a statistically significant RFS benefit (hazard ratio [HR] = 1.47, P = .0015) and OS benefit (HR = 1.52, P = .009) for GMK versus HDI. Similar benefit was observed in the intent-to-treat analysis (RFS HR = 1.49; OS HR = 1.38). HDI was associated with a treatment benefit in all subsets of patients with zero to ≥ four positive nodes, but the greatest benefit was observed in the node-negative subset (RFS HR = 2.07; OS HR = 2.71 [eligible population]). Antibody responses to GM2 (ie, titers ≥ 1:80) at days 29, 85, 365, and 720 were associated with a trend toward improved RFS and OS (P 2= .068 at day 29). CONCLUSION: This trial demonstrated a significant treatment benefit of HDI versus GMK in terms of RFS and OS in melanoma patients at high risk of recurrence.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kirkwood, J. M., Strawderman, M. H., Ernstoff, M. S., Smith, T. J., Borden, E. C., & Blum, R. H. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.1.7 · Cited by 2,094
Self-citationRosenberg, S. A., Yang, J. C., Schwartzentruber, D. J., Hwu, P., Marincola, F. M., Topalian, S. L., Restifo, N. P., Dudley, M. E., Schwarz, S. L., Spiess, P. J., et al. (1998) · Nature Medicine · doi:10.1038/nm0398-321 · Cited by 1,784
Kirkwood, J. M., Ibrahim, J. G., Sondak, V. K., Richards, J., Flaherty, L. E., Ernstoff, M. S., Smith, T. J., Rao, U., Steele, M., & Blum, R. H. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.12.2444 · Cited by 912
Self-citationLivingston, P. O., Wong, G. Y., Adluri, S., Tao, Y., Padavan, M., Parente, R., Hanlon, C., Calves, M. J., Helling, F., & Ritter, G. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.5.1036 · Cited by 516
Jäger, E., Jäger, D., Karbach, J., Chen, Y.-T., Ritter, G., Nagata, Y., Gnjatic, S., Stockert, E., Arand, M., Old, L. J., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.191.4.625 · Cited by 229
Helling, F., Zhang, S., Shang, A., Adluri, S., Calves, M. J., Koganty, R. R., Longenecker, B. M., Yao, T. J., Oettgen, H. F., & Po, L. (1995) · PubMed · Cited by 206
Zarour, H. M., Kirkwood, J. M., Kierstead, L. S., Herr, W., Brusić, V., Slingluff, C. L., Sidney, J., Sette, A., & Storkus, W. J. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.1.400 · Cited by 162
Self-citationHsueh, E. C., Gupta, R. K., Qi, K., & Morton, D. L. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.9.2913 · Cited by 158
NY-ESO-1 encodes DRB1*0401-restricted epitopes recognized by melanoma-reactive CD4+ T cells.
Zarour, H. M., Storkus, W. J., Brusić, V., Williams, E., & Kirkwood, J. M. (2000) · PubMed · Cited by 127
Self-citationKawakami, Y., Dang, N., Wang, X., Tupesis, J. P., Robbins, P. F., Wang, R., Wunderlich, J. R., Yannelli, J. R., & Rosenberg, S. A. (2000) · Journal of Immunotherapy · doi:10.1097/00002371-200001000-00004 · Cited by 124
Ha, P., Schwarz, S. L., Wunderlich, J. R., & Rosenberg, S. A. (1998) · PubMed · Cited by 110
Chapman, P. B., Morrissey, D. M., Panageas, K. S., et al. (2000) · PubMed · Cited by 102
Rivoltini, L., Squarcina, P., Loftus, D. J., Castelli, C., Tarsini, P., Mazzocchi, A., Rini, F., Viggiano, V., Belli, F., & Parmiani, G. (1999) · PubMed · Cited by 94
Håkansson, A., Gustafsson, B., Krysander, L., & Håkansson, L. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.420 · Cited by 86
Ganglioside vaccines with emphasis on GM2.
Livingston, P. O. (1998) · PubMed · Cited by 66
Linette, G. P., Shankara, S., Longerich, S., Yang, S., Doll, R. F., Nicolette, C. A., Preffer, F. I., Roberts, B., & Haluska, F. G. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.6.3402 · Cited by 55
Håkansson, A., GUSTAFSSON, B., Krysander, L., & Håkansson, L. (1998) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.1998.18.33 · Cited by 40
Hsueh, E. C., Famatiga, E., Gupta, R. K., Qi, K., & Morton, D. L. (1998) · Annals of Surgical Oncology · doi:10.1007/bf02303828 · Cited by 34
Caraceni (1998) · doi:10.1002/(sici)1097-0142(19980801)83:3
(2000) · doi:10.1002/1097-0142(20000715)89:2
Cited by
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Cytokines in cancer pathogenesis and cancer therapy
Dranoff, G. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1252 · Cited by 1,573
Shared and Distinct Functions of Type I and Type III Interferons
Lazear, H. M., Schoggins, J. W., & Diamond, M. S. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.025 · Cited by 1,138
Weber, J. S., Carlino, M. S., Khattak, A., Meniawy, T., Ansstas, G., Taylor, M. H., Kim, K. B., McKean, M., Long, G. V., Sullivan, R. J., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(23)02268-7 · Cited by 916
Antitumour actions of interferons: implications for cancer therapy
Parker, B. S., Rautela, J., & Hertzog, P. J. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.14 · Cited by 907
Metadata
- Authors
- Kirkwood, J. M., Ibrahim, J. G., Sosman, J. A., Sondak, V. K., Agarwala, S. S., Ernstoff, M. S., & Rao, U.
- Venue
- Journal of Clinical Oncology
- Published
- 2001-05-01
- Volume
- 19
- Issue
- 9
- Pages
- 2370-2380
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2118449798
- Cited by
- 898
- References
- 20
- FWCI
- 28.49
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.